Ligand Pharmaceuticals Inc (LGND) SEC Filing 8-K Material Event for the period ending Wednesday, March 6, 2019

SEC Filings

Ligand Pharmaceuticals Inc

CIK: 886163 Ticker: LGND

View differences made from one to another to evaluate Ligand Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ligand Pharmaceuticals Inc.


Assess how Ligand Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ligand Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Ligand Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: LGND
CIK: 886163
Form Type: 8-K Corporate News
Accession Number: 0000886163-19-000046
Submitted to the SEC: Wed Mar 06 2019 4:06:06 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Wednesday, March 6, 2019
Industry: Pharmaceutical Preparations
  1. Change in Assets
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: